Transjugular Intrahepatic Portosystemic Shunt Placement: Effects on Nutritional Status in Cirrhotic Patients
- PMID: 38002642
- PMCID: PMC10672441
- DOI: 10.3390/jcm12227029
Transjugular Intrahepatic Portosystemic Shunt Placement: Effects on Nutritional Status in Cirrhotic Patients
Abstract
Malnutrition is a tangible complication of cirrhosis with portal hypertension with a prevalence of up to 50%. In particular, sarcopenia and myosteatosis, defined as the alteration in muscle quantity and quality, have a negative impact on the main complications of liver disease and are associated with higher mortality in patients with cirrhosis. Recently, alterations in adipose tissue have also been described in cirrhotic patients and they seem to influence the course of liver disease. Several pieces of evidence indicate that a transjugular intrahepatic portosystemic shunt (TIPS), placed for the treatment of refractory portal hypertension, can lead to a modification of body composition consisting in the improvement of the skeletal muscle index, myosteatosis, and an increase in subcutaneous fat. These modifications of the nutritional status, even more pronounced in sarcopenic patients before TIPS, have been associated with an amelioration of cognitive impairment after TIPS as well as with an increase in the survival rate. The aim of this paper is to provide an overview of the effects of TIPS placement on nutritional status in cirrhosis focusing on its pathophysiological mechanisms and its relationship with liver-related outcomes.
Keywords: malnutrition; myosteatosis; portal hypertension; sarcopenia; transjugular intrahepatic portosystemic shunt.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Impact of nutritional status on the outcome of transjugular intrahepatic portosystemic shunt in patients with cirrhosis: a systematic review.Br J Radiol. 2024 Feb 2;97(1154):331-340. doi: 10.1093/bjr/tqad065. Br J Radiol. 2024. PMID: 38276881
-
The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.Liver Int. 2021 Dec;41(12):2965-2973. doi: 10.1111/liv.15060. Epub 2021 Sep 28. Liver Int. 2021. PMID: 34543504 Free PMC article.
-
Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt.World J Gastroenterol. 2023 May 14;29(18):2875-2887. doi: 10.3748/wjg.v29.i18.2875. World J Gastroenterol. 2023. PMID: 37274064 Free PMC article.
-
Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.Cochrane Database Syst Rev. 2018 Oct 31;10(10):CD001023. doi: 10.1002/14651858.CD001023.pub3. Cochrane Database Syst Rev. 2018. PMID: 30378107 Free PMC article.
-
Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement.Radiology. 2022 Jun;303(3):711-719. doi: 10.1148/radiol.211172. Epub 2022 Mar 15. Radiology. 2022. PMID: 35289658
References
-
- Thomsen K.L., Sandahl T.D., Holland-Fischer P., Jessen N., Frystyk J., Flyvbjerg A., Grønbæk H., Vilstrup H. Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism. Clin. Nutr. 2012;31:940–945. doi: 10.1016/j.clnu.2012.04.001. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources